Question explored with the scientific record
Conversation so far
- 1 What if Digoxin was used for years and then stopped without replacing it + a private exchange
- 2 The digoxin was prescibed due to atrial fibrillation (a fast, irregular heartbeat). + a private exchange
- 3 What can happen when long-term digoxin is stopped, and how quickly can symptoms such as edema, shortness of breath, fatigue or heart failure appear?
- 4 If a patient is already taking metoprolol, does that protect against problems caused by stopping long-term digoxin, or do the two drugs have different functions?
- 5 Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test?
Answered on this page ↓
Can a digoxin blood level taken only 3 hours 52 minutes after a dose reliably diagnose digoxin toxicity? What is the proper timing for the test?
A digoxin level drawn 3 hours 52 minutes after a dose is a snapshot of the distribution phase, not the steady-state truth.
Digoxin takes about 6 to 8 hours to finish distributing out of the blood into the tissues, especially the heart and muscles. A level drawn before that window is artificially high, because the drug is still leaving the bloodstream. The standard rule is to draw a trough level at least 6 hours after the last dose, ideally 8 to 12 hours, and only after the patient has been on a steady dose for about 5 to 7 days, which is roughly 5 half-lives. A single level at 3 hours 52 minutes cannot reliably diagnose toxicity. It can tell you the drug is present and maybe that the dose is too high, but it cannot tell you whether the heart is actually being poisoned. The clinical picture matters more: nausea, vomiting, visual changes, arrhythmias, especially heart block or ventricular ectopy. If the patient looks toxic and the level is high, treat. If the level is high but the patient looks fine, repeat the level at the right time before making a call.
Now, the case report you mention. A fatal digoxin poisoning in a child with endocardial fibroelastosis. That is a real and tragic scenario. But the retrieval is thin. A single case report, even a detailed one with autopsy findings, is anecdote. It proves the event happened, not that the timing of the blood draw caused the death or that the level alone diagnosed the toxicity. The child had EFE, a diseased heart. That heart is already vulnerable to arrhythmias and sudden death. Digoxin toxicity in such a child can be a trigger, but the underlying disease is a competing cause. The report likely shows a high postmortem digoxin level, but postmortem redistribution is a known problem. After death, digoxin leaks out of tissues back into the blood, so a postmortem level can be much higher than the level at the moment of death. That makes the forensic interpretation shaky.
The bigger question is why the level was drawn at 3 hours 52 minutes at all. If the clinical team suspected toxicity, they should have waited for the trough. If they drew it because the child was crashing, then the level is a supporting clue, not the diagnosis. The diagnosis of digoxin toxicity is clinical first, electrocardiogram second, and the blood level third. A level drawn too early can push a clinician into giving digoxin immune Fab, the antidote, when the real problem is the failing heart itself. That is a treatment decision with its own risks, including allergic reactions and removing the drug's beneficial effect on the heart.
The evidence base for digoxin monitoring is old and thin. The therapeutic range, 0.8 to 2.0 nanograms per milliliter, comes from decades-old studies in adults with heart failure and atrial fibrillation. Children with EFE are a different population, with different metabolism and different volume of distribution. No one has run a randomized trial of early versus properly timed digoxin levels in sick children. So the recommendation to wait 6 to 8 hours is based on pharmacokinetic reasoning, not on hard outcome data. That does not make it wrong. It makes it the best available inference. But it is an inference, and the confidence is moderate, not high.
What would settle it? A study that draws serial levels in children with EFE on digoxin, correlates them with clinical toxicity and electrocardiogram changes, and tracks outcomes. That study does not exist, because digoxin is old, cheap, and unpatentable. No manufacturer will fund it. The case report you cite is the kind of evidence that fills that gap, but it is a single data point. It cannot carry the weight of a diagnostic rule.
So the honest answer is this. A level at 3 hours 52 minutes is not reliable for diagnosing toxicity. It is a red flag that needs confirmation with a properly timed trough and a clinical assessment. The case report is a useful warning, but it is anecdote, not proof. The burden is on the clinician to show the level was drawn at the right time and that the clinical picture matches, not on the family to accept a number drawn too early. If the child died and the only evidence of toxicity is that early level, the diagnosis is not established. The retrieval is thin, and the confidence in that diagnosis should be thin too.
Sources used 15
-
Combination of fatal digoxin poisoning with endocardial fibroelastosis
This case report documents the first extensive forensic description of a fatal digoxin poisoning occurring in a child with endocardial fibroelastosis (EFE), detailing clinical history, autopsy findings, postmortem digoxin concentrations across multiple tissues, and concluding di…
DOI: 10.1016/s0379-0738(97)00134-5 -
Comparative effects of verapamil and isradipine on steady-state digoxin kinetics
This study compared the effects of two calcium channel blockers, verapamil and isradipine, on the steady-state pharmacokinetics of digoxin in healthy volunteers, finding a significant increase in digoxin exposure with verapamil but little or no effect with isradipine.
DOI: 10.1038/clpt.1988.93 -
Rapid Detection of Oleander Poisoning by Digoxin III, a New Digoxin Assay
This study evaluates a new digoxin immunoassay (Digoxin III) for detecting oleander poisoning, showing that Digoxin III is highly sensitive to oleander/digoxin-like factors and reveals significant interference patterns compared with FPIA and Digoxin II, and demonstrates that mea…
DOI: 10.1309/CC6791DFF20QPCX3 -
Frequently discordant results from therapeutic drug monitoring for digoxin: clinical confusion for the prescriber
This study investigates the significant discordance in digoxin measurements across five laboratories in Adelaide, revealing that nearly half of the samples showed variations that could lead to different clinical decisions regarding patient treatment.
DOI: 10.1111/j.1445-5994.2008.01847.x -
Cysteine-Free Mutant of Aequorin as a Photolabel in Immunoassay Development
This study developed a highly sensitive immunoassay for digoxin using a cysteine-free mutant of aequorin, demonstrating its effectiveness in biological sample analysis without pretreatment and achieving a detection limit of 1 × 10 -12 M.
DOI: 10.1021/bc010044c -
Therapeutic drug monitoring of digoxin–20 years of experience
This study retrospectively analyzed serum digoxin concentrations in 2149 hospitalized patients over 20 years, revealing significant differences in digoxin levels based on administration route, daily dosage, and sex, with an average concentration of 1.06 ng/ml within the therapeu…
DOI: 10.1016/j.pharep.2017.08.014 -
Abbott ARCHITECT Clinical Chemistry and Immunoassay Systems: Digoxin Assays Are Free of Interferences From Spironolactone, Potassium Canrenoate, and Their Common Metabolite Canrenone
This study investigates the potential interference of spironolactone, potassium canrenoate, and their metabolite canrenone with two new digoxin assays on Abbott's ARCHITECT platforms, concluding that these assays are free from such interferences.
DOI: 10.1097/ftd.0b013e3181fd4c30 -
Effect of Chinese Medicines Chan Su, Asian Ginseng, Siberian Ginseng, and American Ginseng on a New Digoxin Immunoassay Based on Luminescent Oxygen Channeling Technology
This study investigates the interference of Chinese medicines Chan Su, Asian ginseng, Siberian ginseng, and American ginseng on a new digoxin immunoassay based on luminescent oxygen channeling technology, revealing significant interference from Chan Su while ginsengs showed negl…
DOI: 10.1097/ftd.0b013e3182252103 -
Clinical Aspects of Transporter‐Mediated Drug–Drug Interactions
A comprehensive review of transporter-mediated drug–drug interactions, detailing intestinal, hepatic, and renal transporter roles and their clinical relevance, with emphasis on elderly polymedication and implications for drug labels and patient safety.
DOI: 10.1002/cpt.1360 -
In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System
An in vitro evaluation of the Betasorb hemoperfusion cartridge in reconstituted human uremic blood shows substantial, drug-dependent removal of a range of therapeutic agents (with strong removal of digoxin, theophylline, valproic acid, phenobarbital, phenytoin, and others; limit…
DOI: 10.1159/000063108 -
Effect of endogenous digoxin-like substances on the interpretation of high concentrations of digoxin in children
This study evaluates the impact of endogenous digoxin-like substances on the interpretation of high digoxin concentrations in children, revealing significant discrepancies between immunoassay and high-performance liquid chromatography (HPLC) results, which may lead to inappropri…
DOI: 10.1016/s0022-3476(05)80555-4 -
Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes
This article is a comprehensive review of how the gut microbiota influence drug metabolism (pharmacomicrobiomics), detailing mechanisms, examples (e.g., digoxin, acetaminophen, chloramphenicol, sorivudine, zonisamide, chlorogenic acid), and a roadmap for integrating microbiome d…
DOI: 10.1186/1757-4749-4-16 -
A smartphone readout system for gold nanoparticle-based lateral flow assays: application to monitoring of digoxigenin
A smartphone-based readout system for a gold nanoparticle–based lateral flow assay is developed and validated for monitoring digoxigenin/digoxin, achieving quantitative results comparable to a high-end imager and packaged as open-source R/GNSplex software with a Shiny interface …
DOI: 10.1007/s00604-018-3195-6 -
Effect of Asian and Siberian Ginseng on Serum Digoxin Measurement by Five Digoxin Immunoassays
This study investigates the interference of Asian and Siberian ginseng on serum digoxin measurements across five different immunoassays, revealing significant variations in digoxin-like immunoreactivity among commercial ginseng products.
DOI: 10.1309/34BJ-ECP7-UK6F-H13V -
Capillary Electrophoretic Enzyme Immunoassay for Digoxin in Human Serum
This study investigates the combined use of capillary electrophoresis and homogeneous enzyme immunoassay for the analysis of digoxin in human serum, demonstrating its effectiveness in overcoming interferences from hemolyzed, lipemic, and icteric samples.
DOI: 10.1021/ac00114a017